Updated:
Cancer Prevention & Research Institute of Texas
Kristen Doyle leads CPRIT, Texas's $6B voter-backed cancer research funder that combines academic grants with biotech company investments.
Cancer Prevention & Research Institute of Texas
CPRIT was created in 2007 by a constitutional amendment that authorized $3 billion in general obligation bonds to fund cancer research and prevention in Texas. The institute's structure is unique among state agencies: voters are the ultimate capital allocators, having reauthorized the mandate in 2019 with another $3 billion. The agency reports to an oversight committee chaired by Cindy Barberio Payne, with day-to-day operations run by CEO Kristen Doyle, who assumed the role in July 2024 after serving as the institute's general counsel. CPRIT's deployment model splits into two streams — academic research grants and product development awards. On the academic side, major grantees include the University of Texas MD Anderson Cancer Center, which has received over $725 million, UT Southwestern Medical Center, and Baylor College of Medicine. The product development track operates like a public-sector venture fund, placing non-dilutive capital into Texas-based biotech and oncology startups via its CPRIT Foundation, also known as the Texas Cancer Coalition. The institute targets the valley of death between lab discovery and commercial viability, backing therapeutics, diagnostics, and medical devices. In July 2024, CEO Kristen Doyle formally assumed leadership, inheriting an agency that had already catalyzed multiple FDA-approved drugs and built the Accelerator for Cancer Medical Devices in partnership with the Texas Medical Center. The institute's capital base comes from state bond proceeds rather than a corpus or endowment, making its deployment capacity a function of state debt issuance rather than investment returns. CPRIT does not manage a portfolio in the traditional sense — it exhausts allocations via grants and yield-based recoupment provisions on company awards. The structural differentiator is CPRIT's hybrid identity: a government body that acts like an innovation agency with venture-selective authority. Its product development review panels include scientific experts and commercial reviewers, mimicking an institutional investment committee but operating under public transparency rules. Grant terms for companies often carry royalty provisions or revenue-sharing clauses that return proceeds to the state treasury, creating a closed-loop funding model rare among cancer institutes.
General information
Firm type
Government / Public Body
Year founded
2007
AUM
$3B+ in bonds authorized and disbursed (Altss estimate)
Location
Region
North America
Country
United States
City
Austin
Corporate office
Austin, TX, United States
Principals
Kristen Doyle
Chief Executive Officer
Cindy Barberio Payne
Presiding Officer, Oversight Committee
Sector focus
Frequently asked questions
Where does CPRIT's funding come from?
CPRIT is funded by general obligation bonds authorized by Texas voters. The initial authorization of $3 billion passed in 2007, and a second $3 billion tranche was approved in 2019. This is not an endowment — the institute draws on bond proceeds over time and disburses them as grants and product development awards. It does not raise capital from third-party LPs.
How does CPRIT invest in private companies?
CPRIT's Product Development Research program functions like a non-dilutive grant vehicle for Texas-based life sciences companies. Recipients typically receive milestone-based funding for therapeutics, diagnostics, or devices, and the state may negotiate royalty or revenue-sharing agreements. The institute does not take equity in portfolio companies.
Who makes the investment decisions at CPRIT?
Decision-making is distributed: the Oversight Committee provides governance, while peer review panels composed of external scientific and commercial experts evaluate applications. The CEO — currently Kristen Doyle since July 2024 — manages the operational execution of these recommendations. Final funding authority rests with the Oversight Committee.
Which Texas institutions receive the most CPRIT funding?
University of Texas MD Anderson Cancer Center has received over $725 million since the institute's founding in 2007, making it the largest individual grantee. UT Southwestern Medical Center and Baylor College of Medicine are also top-tier recipients on the academic side. On the commercial side, CPRIT has backed dozens of Texas biotech startups.
Is CPRIT related to the National Cancer Institute?
CPRIT operates independently from the NCI but is recognized as an NCI-approved funding organization. The institute is frequently described as the second-largest public funder of cancer research in the United States, following the NCI. It focuses exclusively on Texas-based institutions and companies, while the NCI has a national scope.
Does CPRIT only fund research, or does it also fund prevention?
CPRIT funds both. The institute's mandate explicitly covers cancer prevention programs, including community-based screening, education, and early detection initiatives across Texas. Its prevention division operates alongside the academic research and product development arms, with separate application and review tracks for each.
How is CPRIT's performance measured or recouped?
CPRIT tracks return on investment through royalty and revenue-sharing provisions attached to its product development awards. Funds recouped return to the state treasury. Additionally, the institute reports economic impact metrics — jobs created, follow-on funding attracted by portfolio companies, and FDA approvals enabled — to the Texas legislature and public.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: